Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 142 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014', provides an overview of the Transitional Cell Cancer (Urothelial Cell Cancer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Transitional Cell Cancer (Urothelial Cell Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Transitional Cell Cancer (Urothelial Cell Cancer) Overview 9
Therapeutics Development 10
Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Overview 10
Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis 11
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics under Development by Companies 12
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Transitional Cell Cancer (Urothelial Cell Cancer) - Products under Development by Companies 17
Transitional Cell Cancer (Urothelial Cell Cancer) - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
Astellas Pharma Inc. 20
AstraZeneca PLC 21
Boston Biomedical, Inc. 22
Daiichi Sankyo Company, Limited 23
Dendreon Corporation 24
Eli Lilly and Company 25
Exelixis, Inc. 26
GlaxoSmithKline plc 27
Innate Therapeutics Limited 28
Merck & Co., Inc. 29
Merck KGaA 30
Mirati Therapeutics Inc. 31
Novartis AG 32
Sanofi 33
Sumitomo Dainippon Pharma Co., Ltd. 34
Teva Pharmaceutical Industries Limited 35
TRACON Pharmaceuticals, Inc. 36
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AGS-15E - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ALT-801 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
amrubicin hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASG-15ME - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AZD-4547 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BBI-503 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
buparlisib hydrochloride - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cabazitaxel - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
cabozantinib s-malate - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CEP-11981 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dovitinib lactate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
enfortumab vedotin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
lapuleucel-t - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MIS-416 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
mocetinostat - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MSB-0010718C - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pembrolizumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ramucirumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SAR-408701 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SNX-5422 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
tigatuzumab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
trametinib dimethyl sulfoxide - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TRC-105 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Transitional Cell Cancer (Urothelial Cell Cancer) - Recent Pipeline Updates 101
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects 135
Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products 137
Transitional Cell Cancer (Urothelial Cell Cancer) - Product Development Milestones 138
Featured News & Press Releases 138
May 14, 2014: Dendreon Announces Presentation of DN24-02 Immuno-Oncology Data at the 2014 ASCO Annual Meeting 138
Jan 30, 2014: Dendreon Announces Presentation of DN24-02 Data at the 2014 Genitourinary Cancer Symposium 138
May 31, 2013: Dendreon Announces Presentation Of DN24-02 Data At 2013 ASCO Annual Meeting 139
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 139
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 142
Disclaimer 142

List of Tables
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2014 10
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Development by Companies, H2 2014 (Contd..1) 18
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Altor BioScience Corporation, H2 2014 19
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Astellas Pharma Inc., H2 2014 20
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by AstraZeneca PLC, H2 2014 21
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Boston Biomedical, Inc., H2 2014 22
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 23
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Dendreon Corporation, H2 2014 24
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2014 25
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Exelixis, Inc., H2 2014 26
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by GlaxoSmithKline plc, H2 2014 27
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Innate Therapeutics Limited, H2 2014 28
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck & Co., Inc., H2 2014 29
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck KGaA, H2 2014 30
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H2 2014 31
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Novartis AG, H2 2014 32
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sanofi, H2 2014 33
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 34
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 35
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Recent Pipeline Updates, H2 2014 101
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects, H2 2014 135
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects (Contd..1), H2 2014 136
Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products, H2 2014 137